J9334 Injection efgart-alfa 2mg hya-qvfc
Also known as: efgartigimod hyaluronidase, Vyvgart Hyaluronidase
Injection of efgartigimod alfa with hyaluronidase (efgart-alfa hya-qvfc), 2 milligram. Enhanced subcutaneous FcRn antagonist formulation.
In Plain Language
muscle weakness treatment; autoimmune disease injection
Clinical Context
Subcutaneous formulation of efgartigimod for myasthenia gravis and autoimmune conditions. Enhanced delivery via hyaluronidase.
RVU Information
CPT J9334 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9334?
CPT J9334 (Injection efgart-alfa 2mg hya-qvfc) is a J Codes (Drugs) code. Injection of efgartigimod alfa with hyaluronidase (efgart-alfa hya-qvfc), 2 milligram. Enhanced subcutaneous FcRn antagonist formulation.
How is J9334 administered?
CPT J9334 is administered by a healthcare provider, typically via injection or infusion. Subcutaneous formulation of efgartigimod for myasthenia gravis and autoimmune conditions. Enhanced delivery via hyaluronidase. It is used by Neurology, Rheumatology, Internal Medicine.
When is CPT J9334 used?
Subcutaneous formulation of efgartigimod for myasthenia gravis and autoimmune conditions. Enhanced delivery via hyaluronidase.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.